2024 Volume 6 Issue 1 Pages 16-17
A 67-year-old man who had been taking azilsartan 20 mg/day and eicosapentaenoic acid 1.8 g/day presented with atypical chest pain and underwent coronary computed tomography angiography (CCTA) to assess coronary artery disease as described in the Supplementary Methods. CCTA showed a 50–69% stenosis with low-density plaques in the proximal left anterior descending artery (Figure A; Supplementary Figure). Fractional flow reserve on CCTA (FFRCT), measured approximately 2 cm distal to the stenosis, indicated positive ischemia (Figure C). Furthermore, the difference in FFRCT values proximal and distal to the lesion (∆FFRCT) was 0.21 (Figure C). At the 2-year follow-up after starting rosuvastatin 5 mg/day, low-density lipoprotein concentrations had decreased from 146 to 56 mg/dL with subsequent improvement in symptoms. CCTA showed an improvement in distal FFRCT and ∆FFRCT from 0.76 to 0.88 and from 0.21 to 0.09, respectively (Figure D), and a mild improvement in the stenosis with an increase in density (Figure B; Supplementary Figure).
(A,B) Stretched views show moderate stenosis at the middle of the left anterior descending artery (arrow) at baseline (A) and follow-up (B). (C,D) Three-dimensional model showing fractional flow reserve derived from coronary computed tomography angiography (FFRCT) values at baseline (C) and follow-up (D).
This case demonstrates the usefulness of FFRCT for evaluation of coronary ischemia after lipid-lowering therapy. FFRCT predicts lesion-specific ischemia compared with invasive FFR. Patients with distal FFRCT >0.8 have a better prognosis.1 A study also demonstrated that greater ∆FFRCT is associated with an increase in cardiovascular events.2 Our patient’s distal FFRCT and ∆FFRCT improved after lipid-lowering therapy, suggesting the usefulness of FFRCT for clinically assessing improvement in coronary ischemia with lipid-lowering therapy.
Please find supplementary file(s);
https://doi.org/10.1253/circrep.CR-23-0091